Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment-Reference-Cited by-同舟云学术

Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment

Published:2019-03-28 Issue:6 Volume:85 Page:1239-1246
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Saif Muhammad Wasif¹^ORCID,Rosen Lee²,Rudek Michelle A.³,Sun Weijing⁴,Shepard Dale R.⁵,Becerra Carlos⁶,Yamashita Fumiaki⁷,Bebeau Paul⁷,Winkler Robert⁷

Affiliation:

1. Northwell Health Cancer Institute Lake Success NY USA

2. University of California Los Angeles CA USA

3. Johns Hopkins University Baltimore MD USA

4. University of Kansas Kansas City KS USA

5. Cleveland Clinic Cleveland OH USA

6. Texas OncologyBaylor University Medical Center Dallas TX USA

7. Taiho Oncology, Inc Princeton NJ USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13856

Reference15 articles.

1. A novel combination antimetabolite, TAS‐102, exhibits antitumor activity in FU‐resistant human cancer cells through a mechanism involving FTD incorporation in DNA;Emura T;Int J Oncol,2004

2. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides

3. A novel antimetabolite, TAS‐102 retains its effect on FU‐related resistant cancer cells;Emura T;Int J Mol Med,2004

4. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors

5. Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioanalytical method development for quantification of trifluridine with its metabolites and tipiracil in spiked human plasma by solid-phase extraction (SPE) and HPLC with PDA detection;Materials Today: Proceedings;2023-06

2. A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions;Cancer Chemotherapy and Pharmacology;2023-01-09

3. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer;ESMO Open;2022-12

4. Pyrimidine-based anticancer drugs;New Strategies Targeting Cancer Metabolism;2022

5. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment;Cancer Chemotherapy and Pharmacology;2021-06-07